Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study

INTRODUCTION: We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligand 1 and programmed death-ligand 2), in Japanese patients with malignant pleural...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimoto, Nobukazu, Okada, Morihito, Kijima, Takashi, Aoe, Keisuke, Kato, Terufumi, Nakagawa, Kazuhiko, Takeda, Yuichiro, Hida, Toyoaki, Kanai, Kuninobu, Hirano, Jun, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474205/
https://www.ncbi.nlm.nih.gov/pubmed/34589998
http://dx.doi.org/10.1016/j.jtocrr.2020.100135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474205/
https://www.ncbi.nlm.nih.gov/pubmed/34589998
http://dx.doi.org/10.1016/j.jtocrr.2020.100135

Ejemplares similares